Regulus Therapeutics Announces Completion of Enrollment in Fourth Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Stock Information for Applied UV Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Applied UV Inc.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RGLS, KRON, XAGE, SSBK on Behalf of Shareholders
Regulus Therapeutics Reports First Quarter 2025 Financial Results and Recent Updates
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RGLS, KRON, PPBI, COEP on Behalf of Shareholders
REGULUS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Regulus Therapeutics Inc. - RGLS
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RGLS, KRON, SWTX on Behalf of Shareholders
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Regulus Therapeutics Inc. Buyout
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Regulus Therapeutics Inc. - RGLS
RGLS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Regulus Therapeutics Inc. Is Fair to Shareholders

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.